Shots:

• Sun Pharma has filed manufacturing and marketing authorization of Tildrakizumab to the PMDA for moderate-to-severe psoriasis and psoriatic arthritis in Japan
• Additionally- Sun Pharma has acquired Pola Pharma and will leverage Pola’s strong presence in the dermatology to commercialize Tildrakizumab in Japan which will expand Sun Pharma’s global franchise and robust its dermatology pipeline
• Tildrakizumab-asmn is an lgG1/k mAb targeting p19 subunit of IL-23- inhibiting its interaction with IL-23- resulting in inhibition of release of pro-inflammatory cytokines and chemokines and is an approved therapy in the US & Australia as Ilumya and in Europe as Ilumetri

Click here to­ read full press release/article | Ref: Sun Pharma | Image: Pinterest